ABC
RARE icon

Associated Banc-Corp’s Ultragenyx Pharmaceutical RARE Stock Holding History

Associated Banc-Corp’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28
Closed -$4K – 729
2020
Q4 		$4K Hold
28
– – ﹤0.01% 567
2020
Q3 		$2K Hold
28
– – ﹤0.01% 734
2020
Q2 		$2K Buy
+28
New +$1.85K ﹤0.01% 734

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Associated Banc-Corp's RARE Position: Q1 2021 in Review

Associated Banc-Corp sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 28 shares — an estimated $4K sold.

Associated Banc-Corp first reported a position in RARE in Q2 2020 and held it in 3 quarters. The position peaked at $4K in Q4 2020. 254 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

  • Associated Banc-Corp reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Associated Banc-Corp sold 28 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $4K.
  • Associated Banc-Corp first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 3 quarters.
  • Associated Banc-Corp's Ultragenyx Pharmaceutical position peaked at $4K in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on Associated Banc-Corp's 13F filing for Q1 2021, filed 5 May 2021.